Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
AssigneeLunella Biotech, Inc.
InventorsMichael P. Lisanti, Federica Sotgia
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds that bind to flavin-containing enzymes and inhibit mitochondrial function, referred to herein as mitoflavoscins. Methods of screening compounds for mitochondrial inhibition and anti-cancer properties are disclosed. Also described are methods of using mitoflavoscins to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitoflavoscins to provide anti-aging benefits. Specific mitoflavoscin compounds are also disclosed.
Claims19
A mitoflavoscin having at least one fatty acid membrane-targeting signal selected from the group consisting of palmitic acid, stearic acid, myristic acid, and oleic acid.
A pharmaceutical composition comprising, as the active ingredient, at least one mitoflavoscin, wherein the mitoflavoscin has at least one fatty acid membrane-targeting signal selected from the group consisting of palmitic acid, stearic acid, myristic acid, and oleic acid.
Dependencies are inferred from the claim text.